Silvano Dragonieri
Overview
Explore the profile of Silvano Dragonieri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Portacci A, Iorillo I, Quaranta V, Amendolara M, Sana F, Pezzuto V, et al.
Respir Med
. 2025 Feb;
239:108008.
PMID: 39978606
Background: Asthma is a chronic respiratory disease characterized by airway inflammation and variable respiratory symptoms. While peripheral muscle deconditioning is known to affect lung function and exercise tolerance, the role...
2.
Carratu P, Dragonieri S, Quaranta V, Resta O, Portincasa P, Palmieri V, et al.
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518499
This study evaluated the impact of continuous positive airway pressure (C-PAP) therapy combined with a rigorous diet regimen on obese patients with obstructive sleep apnea syndrome (OSAS). Sixty obese patients...
3.
Quaranta V, Portacci A, Montagnolo F, Dragonieri S, Iorillo I, Lulaj E, et al.
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518449
Patients with severe asthma (SA) and non-cystic fibrosis bronchiectasis (BE) without microbiological colonization represent a unique and understudied population. Type 2-targeted biologic therapies have emerged as a promising treatment for...
4.
Di Bona D, Paoletti G, Ordak M, Dragonieri S, Cognet-Sice J, Scurati S, et al.
World Allergy Organ J
. 2024 Nov;
17(11):100985.
PMID: 39512672
Background: In the realm of allergen immunotherapy (AIT), the quality of evidence varies across different products, making it unjustifiable to extend overall conclusions to all AIT products, as highlighted by...
5.
Dragonieri S, Bikov A
J Clin Med
. 2024 Oct;
13(19).
PMID: 39407909
The field of respiratory disease diagnostics has been propelled forward by recent innovations in biomarker research [...].
6.
Tondo P, Scioscia G, Di Marco M, Quaranta V, Campanino T, Palmieri G, et al.
Molecules
. 2024 Sep;
29(18).
PMID: 39339353
This study investigates volatile organic compound (VOC) profiles in the exhaled breath of normal subjects under different oxygenation conditions-normoxia (FiO2 21%), hypoxia (FiO2 11%), and hyperoxia (FiO2 35%)-using an electronic...
7.
Dragonieri S, Portacci A, Quaranta V, Carratu P, Lazar Z, Carpagnano G, et al.
Diseases
. 2024 Sep;
12(9).
PMID: 39329893
Obstructive Sleep Apnea (OSA) is a prevalent disorder characterized by repetitive upper airway obstructions during sleep, leading to intermittent hypoxia and sleep fragmentation. Current treatments, particularly Continuous Positive Airway Pressure...
8.
Carpagnano G, Dragonieri S, Resta E, Lulaj E, Montagnolo F, Portacci A, et al.
J Asthma
. 2024 Sep;
62(3):456-464.
PMID: 39325583
Objective: Severe asthma presents significant management challenges, often requiring advanced treatments to control symptoms and reduce exacerbations. The use of monoclonal antibodies has revolutionized the clinical course of patients with...
9.
Finamore P, Arena E, Lupoi D, Savito L, Di Nunzio F, Furbatto M, et al.
J Clin Med
. 2024 Aug;
13(16).
PMID: 39200898
The COVID-19 pandemic has led to the emergence of post-acute COVID-19 syndrome, also known as long COVID, which presents a significant challenge due to its varied symptoms and unpredictable course,...
10.
Crimi C, Nolasco S, Noto A, Maglio A, Quaranta V, Di Bona D, et al.
J Allergy Clin Immunol Pract
. 2024 Aug;
12(12):3315-3327.
PMID: 39197750
Background: Biological therapies, such as mepolizumab, have transformed the treatment of severe eosinophilic asthma. Although mepolizumab's short-term effectiveness is established, there is limited evidence on its ability to achieve long-term...